Covalon Reports 2026 Second Quarter Results
Covalon doubles down on infection prevention as CovaClear U.S. sales soar sixfold; zero-debt balance sheet and surging margins fuel re-rating.
The most recent release (May 21, 2026) reports Covalon’s fiscal Q2 2026 results. Revenue grew 15% YoY to $8.7 million, gross margin expanded 690 bps to 61.5%, and net income jumped 155% to $1.09 million ($0.04 diluted EPS). U.S. revenue for CovaClear® Cover dressings doubled sequentially and rose more than sixfold YoY. A major northeastern U.S. hospital adopted the product across 30+ locations. Cash stands at $16.6 million with zero bank debt. CEO Brent Ashton expressed confidence that the company is “only beginning to scratch the surface.”
Earlier releases show a steady build: FY2025 full-year revenue hit $32.8 million (+5% YoY) with a first-ever special dividend of $0.15 CAD per share. Q1 2026 was roughly breakeven, but management signaled a strong Q2 pipeline—now confirmed. Throughout, the company highlighted clinical wins (published CLABSI reduction studies), new hospital system approvals (300-site IDN), and expanding partnership with Hartmann USA via Vizient.
The Q2 results materially exceed the cautious tone set by the prior Q1 (breakeven with margin compression). Revenue growth re-accelerated, margins surged well above the FY2025 average, and profitability returned to a meaningful level. The doubling of CovaClear IV Cover revenue QoQ suggests real adoption momentum, not just one-off orders. The balance sheet remains pristine—$16.6M cash, no debt—removing dilution risk. The stock had been languishing near multi-year lows, so this release is a positive shock that can force a re-rating. I therefore classify it as material and positive. The news is not a game changer (no first-time marquee investor, no M&A), but it fundamentally shifts the near-term earnings trajectory in a way the market did not fully price in.
Covalon Technologies Ltd. develops and commercializes advanced medical products focused on infection prevention, vascular access, and wound care. Its flagship “Contamination Prevention” category includes VALGuard® Vascular Access Line Guard and CovaClear® IV Cover dressings, designed to reduce central line-associated bloodstream infections (CLABSI). The company also sells collagen-based wound dressings (ColActive® Plus) through partnerships. Clinical evidence from multiple pediatric and adult studies underpins the product value proposition.